FDA As Drug Developer: Voucher For AstraZeneca, Orphan Indication For Wellstat
Executive Summary
Hoping to head off shortage of another product, FDA’s intervention gives both Wellstat and AstraZeneca quicker paths to market for their drugs in what could almost be a regulatory fairytale.